Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred Morgenstern

Showing results (141-150 of 179) with videos related to

Pageof 18
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2013
213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myelomaMichel Chérel, Sébastien Gouard, Joëlle Gaschet, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 2, 2023
<sup>225</sup>Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findingsMike Sathekge, Frank Bruchertseifer, Mariza Vorster, et al.
Cancer Biology & Therapy|May 15, 2007
Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanomaChand Raja, Peter Graham, Syed M Abbas Rizvi, et al.
Plos One|May 30, 2009
Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cellsEnken Drecoll, Florian C Gaertner, Matthias Miederer, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 27, 2006
In vitro screening for synergism of high-linear energy transfer 213Bi-radiotherapy with other therapeutic agents for the treatment of B-cell chronic lymphocytic leukemiaKatia Vandenbulcke, Hubert Thierens, Filip De Vos, et al.
International Journal of Radiation Oncology, Biology, Physics|October 26, 2021
Targeted Alpha Particle Therapy Remodels the Tumor Microenvironment and Improves Efficacy of ImmunotherapyJustine Perrin, Marisa Capitao, Mathilde Allard, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2025
[<sup>225</sup>Ac]Ac-PSMA I&T: A Preclinical Investigation on the Fate of Decay Nuclides and Their Influence on Dosimetry of Salivary Glands and KidneysAlexander Wurzer, Baiqing Sun, Samaa Saleh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bilabeled multiple targeted alpha radioimmunoconjugatesYong Li, Emma Song, Syed M Abbas Rizvi, et al.
Frontiers in Medicine|October 12, 2016
Combination of Antiretroviral Drugs and Radioimmunotherapy Specifically Kills Infected Cells from HIV-Infected IndividualsDina Tsukrov, Alicia McFarren, Alfred Morgenstern, et al.
Pharmaceutics|June 2, 2021
Development of [<sup>225</sup>Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPCEline L Hooijman, Yozlem Chalashkan, Sui Wai Ling, et al.
Pageof 18

Showing results (141-150 of 179) with videos related to

Sort By:
Pageof 18
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2013
213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myelomaMichel Chérel, Sébastien Gouard, Joëlle Gaschet, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 2, 2023
<sup>225</sup>Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findingsMike Sathekge, Frank Bruchertseifer, Mariza Vorster, et al.
Cancer Biology & Therapy|May 15, 2007
Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanomaChand Raja, Peter Graham, Syed M Abbas Rizvi, et al.
Plos One|May 30, 2009
Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cellsEnken Drecoll, Florian C Gaertner, Matthias Miederer, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 27, 2006
In vitro screening for synergism of high-linear energy transfer 213Bi-radiotherapy with other therapeutic agents for the treatment of B-cell chronic lymphocytic leukemiaKatia Vandenbulcke, Hubert Thierens, Filip De Vos, et al.
International Journal of Radiation Oncology, Biology, Physics|October 26, 2021
Targeted Alpha Particle Therapy Remodels the Tumor Microenvironment and Improves Efficacy of ImmunotherapyJustine Perrin, Marisa Capitao, Mathilde Allard, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2025
[<sup>225</sup>Ac]Ac-PSMA I&T: A Preclinical Investigation on the Fate of Decay Nuclides and Their Influence on Dosimetry of Salivary Glands and KidneysAlexander Wurzer, Baiqing Sun, Samaa Saleh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bilabeled multiple targeted alpha radioimmunoconjugatesYong Li, Emma Song, Syed M Abbas Rizvi, et al.
Frontiers in Medicine|October 12, 2016
Combination of Antiretroviral Drugs and Radioimmunotherapy Specifically Kills Infected Cells from HIV-Infected IndividualsDina Tsukrov, Alicia McFarren, Alfred Morgenstern, et al.
Pharmaceutics|June 2, 2021
Development of [<sup>225</sup>Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPCEline L Hooijman, Yozlem Chalashkan, Sui Wai Ling, et al.
Pageof 18